| ￥3300 | |
| Z04982-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 60.56 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 62-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCl, 500mM L Arginine, 2mM DTT (pH 7.0). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Histo-blood group ABH (O) antigens are major alloantigens in humans. These antigens are widely distributed in human tissues and undergo changes in expression during cellular differentiation and malignant development. The ABH antigens have been characterized as terminal disaccharide determinants which represent secondary gene products. They are synthesized in a stepwise fashion from a precursor by the action of different glycosyltransferases. |
| Synonyms | ABH |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
